CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 7 No. 12
 

Make HIV Testing Routine in Prenatal Care, IOM Panel Urges

December 1, 1998

WASHINGTON—HIV testing should be made a routine but voluntary part of prenatal care for all women in the United States, an Institute of Medicine (IOM) committee has recommended.

“We believe that health care providers should notify pregnant women that HIV is part of the usual array of tests they will receive, and women should have the opportunity to refuse the test,” said panel chair Marie McCormick, MD, ScD, professor of maternal and child health, Harvard School of Public Health. “This subtle yet important shift in policy would help reduce the number of pediatric AIDS cases and, as long as it happens in parallel with good medical care, would also improve treatment for mothers with AIDS.”

Women now account for 21% of adult AIDS cases in the United States. The IOM report noted that the use of zidovudine(Drug information on zidovudine) (AZT, Retrovir) in HIV-infected pregnant women had a major role in helping reduce the number of new pediatric AIDS cases by 43% between 1992 and 1996.

Clinical trials have shown that zidovudine can reduce mother-to-child HIV transmission rates to below 5%. About 500 babies will be born this year with full-blown AIDS and as many as 1,500 more with HIV infection.

Making HIV testing routine would reduce the need to provide extensive pre-test counseling required by current guidelines, Dr. McCormick said. It would also end the need for doctors to assess whether a women is at high risk of infection and make extra efforts to encourage high-risk women to be tested.

“By recognizing that HIV is a communicable disease without inherent geographic or human barriers, routine testing would lessen the stigmatization of groups in which perinatal HIV transmission is now more prevalent,” she added.

An analysis showed that the cost of this policy recommendation compares favorably with the cost of treating HIV-infected children.

The panel also urged that the federal government establish a regional system of perinatal HIV prevention and treatment centers. “These centers would help ensure optimal HIV care for all pregnant women and newborns, and would help develop and implement strategies to promote prenatal HIV screening,” she said.

The IOM report, “Reducing The Odds: Preventing Perinatal Transmission of HIV in the United States,” proposed six actions needed to make its testing recommendation a reality:

  • Health care plans should implement policies to facilitate routine prenatal testing, and should track their success in conducting HIV screening.

  •  Businesses and other organizations that purchase health care should support routine prenatal testing in their contracts with providers.
  •  Professional medical organizations should update their guidelines to recommend routine prenatal screening.
  •  Providers need to be educated about the value of prenatal HIV screening and how to deal appropriately with those who test positive.
  •  Health officials need to improve their outreach to pregnant women, to address their concerns about testing and treatment.
  •  Testing should be seamlessly linked to treatment for women found to be infected, and this care must be coordinated before, during, and after delivery. Providers must take steps to ensure their patients’ confidentiality is protected, and that a patient is not forced to take a test.

“We are saying that the process for identifying HIV should be so routine, with informed consent, that it is likely to be universally available,” said panel vice chair Ezra Davidson, Jr., MD, professor of ob/gyn, Charles R. Drew University of Medicine and Science, Los Angeles.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Skin Lesions
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • The ABCDEs of Moles and Melanomas
  • “This Is My Last Day on Earth”
  • Accelerated Partial-Breast Irradiation: The Current State of Our Knowledge
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Colorectal Lesions
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy